NCT00477633

Brief Summary

This is a non-comparative study. the primary objective of the study is to assess the efficacy of a low dose oral contraceptive in the prevention of pregnancy. The secondary objectives are to assess the incidence of intracyclic bleeding; and to assess the safety and tolerability of the product.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,700

participants targeted

Target at P75+ for phase_3

Timeline
Completed

Started Jun 2007

Geographic Reach
1 country

63 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 22, 2007

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 24, 2007

Completed
8 days until next milestone

Study Start

First participant enrolled

June 1, 2007

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2009

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2009

Completed
2 years until next milestone

Results Posted

Study results publicly available

January 24, 2011

Completed
Last Updated

April 22, 2013

Status Verified

April 1, 2013

Enrollment Period

1.6 years

First QC Date

May 22, 2007

Results QC Date

October 13, 2010

Last Update Submit

April 15, 2013

Conditions

Keywords

Contraception

Outcome Measures

Primary Outcomes (1)

  • Pearl Index, 18-35 Years, MITT Population

    Pregnancy rate in women 18-35 years old, Pearl Index - number of pregnancies per 100 women-years of treatment

    13 cycles (28 days each), approximately 364 days

Secondary Outcomes (2)

  • Mean Number of Days of Intracyclic Bleeding & Spotting, Cycles 2-13, MITT Population

    12 cycles (28 days each), approximately 336 days

  • Mean Median Duration (Days) of Intracyclic Bleeding & Spotting, Cycles 2-13, MITT Population

    12 cycles (28 days each), approximately 336 days

Study Arms (1)

Norethindrone/ethinyl estradiol

EXPERIMENTAL

1 tablet per day

Drug: Norethindrone/ethinyl estradiol

Interventions

1 tablet per day

Norethindrone/ethinyl estradiol

Eligibility Criteria

Age18 Years - 45 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Healthy Women
  • Age 18-45
  • At risk for pregnancy
  • History of regular cycles

You may not qualify if:

  • Contraindications for use of hormonal contraception
  • Conditions which affect the absorption or metabolism of steroid hormones
  • BMI\>35

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (63)

Warner Chilcott Investigational Site

Chandler, Arizona, 85224, United States

Location

Warner Chilcott Investigational Site

Phoenix, Arizona, 85032, United States

Location

Warner Chilcott Investigational Site

Phoenix, Arizona, 85037, United States

Location

Warner Chilcott Investigational Site

Phoenix, Arizona, 85050, United States

Location

Warner Chilcott Investigational Site

Tempe, Arizona, 85282, United States

Location

Warner Chilcott Investigational Site

Tucson, Arizona, 85712, United States

Location

Warner Chilcott Investigational Site

San Diego, California, 92103, United States

Location

Warner Chilcott Investigational Site

San Diego, California, 92108, United States

Location

Warner Chilcott Investigational Site

Vista, California, 92083, United States

Location

Warner Chilcott Investigational Site

Castle Rock, Colorado, 80108, United States

Location

Warner Chilcott Investigational Site

Denver, Colorado, 80218, United States

Location

Warner Chilcott Investigational Site

Lakewood, Colorado, 80228, United States

Location

Warner Chilcott Investigational Site

Boynton Beach, Florida, 33472, United States

Location

Warner Chilcott Investigational Site

Brooksville, Florida, 34613, United States

Location

Warner Chilcott Investigational Site

Clearwater, Florida, 33759, United States

Location

Warner Chilcott Investigational Site

Gainesville, Florida, 32607, United States

Location

Warner Chilcott Investigational Site

Jacksonville, Florida, 32207, United States

Location

Warner Chilcott Investigational Site

Leesburg, Florida, 34748, United States

Location

Warner Chilcott Investigational Site

Miami, Florida, 33143, United States

Location

Warner Chilcott Investigational Site

Miami, Florida, 33186, United States

Location

Warner Chilcott Investigational Site

Pembroke Pines, Florida, 33021, United States

Location

Warner Chilcott Investigational Site

St. Petersburg, Florida, 33709, United States

Location

Warner Chilcott Investigational Site

West Palm Beach, Florida, 33401, United States

Location

Warner Chilcott Investigational Site

West Palm Beach, Florida, 33409, United States

Location

Warner Chilcott Investigational Site

Decatur, Georgia, 30034, United States

Location

Warner Chilcott Investigational Site

Champaign, Illinois, 61820, United States

Location

Warner Chilcott Investigational Site

Peoria, Illinois, 61615, United States

Location

Warner Chilcott Investigational Site

Indianapolis, Indiana, 46250, United States

Location

Warner Chilcott Investigational Site

Arkansas City, Kansas, 67005, United States

Location

Warner Chilcott Investigational Site

Wichita, Kansas, 67207, United States

Location

Warner Chilcott Investigational Site

Lexington, Kentucky, 40509, United States

Location

Warner Chilcott Investigational Site

Louisville, Kentucky, 40291, United States

Location

Warner Chilcott Investigational Site

Amite, Louisiana, 70422, United States

Location

Warner Chilcott Investigational Site

Marrero, Louisiana, 70072, United States

Location

Warner Chilcott Investigational Site

Chaska, Minnesota, 55318, United States

Location

Warner Chilcott Investigational Site

Berlin, New Jersey, 08009, United States

Location

Warner Chilcott Investigational Site

Edison, New Jersey, 08817, United States

Location

Warner Chilcott Investigational Site

Lawrenceville, New Jersey, 08648, United States

Location

Warner Chilcott Investigational Site

Moorestown, New Jersey, 08051, United States

Location

Warner Chilcott Investigational Site

New York, New York, 10016, United States

Location

Warner Chilcott Investigational Site

Cary, North Carolina, 27511, United States

Location

Warner Chilcott Investigational Site

New Bern, North Carolina, 28562, United States

Location

Warner Chilcott Investigational Site

Raleigh, North Carolina, 27612, United States

Location

Warner Chilcott Investigational Site

Winston-Salem, North Carolina, 27103, United States

Location

Warner Chilcott Investigational Site

Cleveland, Ohio, 44122, United States

Location

Warner Chilcott Investigational Site

Oklahoma City, Oklahoma, 73112, United States

Location

Warner Chilcott Investigational Site

Medford, Oregon, 97504, United States

Location

Warner Chilcott Investigational Site

Philadelphia, Pennsylvania, 19114, United States

Location

Warner Chilcott Investigational Site

Pittsburgh, Pennsylvania, 15206, United States

Location

Warner Chilcott Investigational Site

Pottstown, Pennsylvania, 19464-3224, United States

Location

Warner Chilcott Investigational Site

Columbia, South Carolina, 29201, United States

Location

Warner Chilcott Investigational Site

Austin, Texas, 78748, United States

Location

Warner Chilcott Investigational Site

Austin, Texas, 78759, United States

Location

Warner Chilcott Investigational Site

Dallas, Texas, 75234, United States

Location

Warner Chilcott Investigational Site

Houston, Texas, 77030, United States

Location

Warner Chilcott Investigational Site

San Antonio, Texas, 78229, United States

Location

Warner Chilcott Investigational Site

Magna, Utah, 84044, United States

Location

Warner Chilcott Investigational Site

Salt Lake City, Utah, 84109, United States

Location

Warner Chilcott Investigational Site

Salt Lake City, Utah, 84121, United States

Location

Warner Chilcott Investigational Site

West Valley City, Utah, 84120, United States

Location

Warner Chilcott Investigational Site

Norfolk, Virginia, 23507, United States

Location

Warner Chilcott Investigational Site

Richmond, Virginia, 23233, United States

Location

Warner Chilcott Investigational Site

Virginia Beach, Virginia, 23456, United States

Location

MeSH Terms

Interventions

ovcon 35

Results Point of Contact

Title
Grexan Wulff, Manager Regulatory Affairs
Organization
Warner Chilcott

Study Officials

  • Herman Ellman

    Sponsor GmbH

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
LTE60
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
phase 3
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 22, 2007

First Posted

May 24, 2007

Study Start

June 1, 2007

Primary Completion

January 1, 2009

Study Completion

February 1, 2009

Last Updated

April 22, 2013

Results First Posted

January 24, 2011

Record last verified: 2013-04

Locations